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Abstract
Introduction: Microglial activation in multiple sclerosis has been postulated to contribute to long-term
neurodegeneration during disease. Fingolimod has been shown to impact on the relapsing remitting phase of
disease by modulating autoreactive T-cell egress from lymph organs. In addition, it is brain penetrant and has been
shown to exert multiple effects on nervous system cells.
Methods: In this study, the impact of fingolimod and other sphingosine-1-phosphate receptor active molecules
following lysophosphotidyl choline-induced demyelination was examined in the rat telencephalon reaggregate,
spheroid cell culture system. The lack of immune system components allowed elucidation of the direct effects of
fingolimod on CNS cell types in an organotypic situation.
Results: Following demyelination, fingolimod significantly augmented expression of myelin basic protein in the
remyelination phase. This increase was not associated with changes in neurofilament levels, indicating de novo
myelin protein expression not associated with axonal branching. Myelin wrapping was confirmed morphologically
using confocal and electron microscopy. Increased remyelination was associated with down-regulation of
microglial ferritin, tumor necrosis factor alpha and interleukin 1 during demyelination when fingolimod was
present. In addition, nitric oxide metabolites and apoptotic effectors caspase 3 and caspase 7 were reduced during
demyelination in the presence of fingolimod. The sphingosine-1-phosphate receptor 1 and 5 agonist BAF312 also
increased myelin basic protein levels, whereas the sphingosine-1-phosphate receptor 1 agonist AUY954 failed to
replicate this effect on remyelination.
Conclusions: The results presented indicate that modulation of S1P receptors can ameliorate pathological effectors
associated with microglial activation leading to a subsequent increase in protein and morphological markers of
remyelination. In addition, sphingosine-1-phosphate receptor 5 is implicated in promoting remyelination in vitro.
This knowledge may be of benefit for treatment of chronic microglial inflammation in multiple sclerosis.
Introduction
Multiple sclerosis (MS), the prototypic inflammatory
demyelinating disease of the central nervous system
(CNS), is considered an autoimmune disorder with a
secondary neurodegenerative component with associated
oligodendrocyte pathology. During the relapsing-remit-
ting disease course evident in the majority of patients,
inflammation is the key driver of disease, with inflam-
matory infiltration correlating with bouts of clinical
symptoms. The typical course changes later in disease,
becoming progressive in nature and lacking periods of
remission. This secondary progressive phase lacks many
of the markers of immune involvement seen in earlier
disease, but displays ongoing demyelination and axonal
loss, which results in a progressive functional decline
[1]. Therapies currently available to people affected by
MS target the immune-related component of the dis-
ease, and none have yet been shown to convincingly
impact on the secondary neurodegenerative phase [2]. It
has been postulated that one mechanism for neuropro-
tection in MS would be remyelination, especially given
that this is the natural reparatory mechanism following
a relapse in MS, and in an animal model, experimental
autoimmune encephalomyelitis (EAE; [3]). As well as
restoring saltatory conduction, remyelination forms a
physical barrier to secondary axonal degeneration in the
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lesion environment. Direct damage to neurons and neu-
ronal apoptosis can be caused by excitotoxic mediators,
neurotoxic cytokines and free radical species present in
chronic MS lesions, in spite of the reduced inflamma-
tory infiltrate [4].
A compound recently licensed for treatment of
relapsing forms of MS, fingolimod (FTY720, approved
as Gilenya™ in US and several other countries), is a
sphingosine-1-phosphate (S1P) receptor modulator
that can cause retention of T-cells in lymph organs
when phosphorlyated to the active form [5]. It is a
potent agonist at S1P1, 4 and 5 receptors, less so at
S1P3, and has minimal activity at S1P2 [5,6]. In addi-
tion, fingolimod can act as a functional antagonist at
S1P1 receptors in lymphocytes by inducing their inter-
nalisation and subsequent degradation [7]. By this
mechanism, the compound reduces immune cell infil-
tration into the CNS, with Phase III trials demonstrat-
ing effects on MRI activity, brain atrophy and relapse
rate [8]. It has been proposed that fingolimod may also
directly affect cells of the CNS [9]. It is blood-brain
barrier penetrant due to its lipophilic nature, can reach
physiologically meaningful concentrations in CNS tis-
sue and preferentially localizes to myelinated tracts
[10]. S1P receptors are expressed on all CNS cell
types, providing a basis for direct CNS effects. S1P
receptor subtype specific agonists have also been
synthesized by Novartis: AUY954 is active at S1P1
receptors [11] and is a tool compound, and BAF312 is
active at S1P1 and S1P5 receptors [12,13] and has
completed phase II clinical trials in MS [8].
In vitro studies on single cell types have identified a
range of effects on CNS cells. S1P signaling in oligoden-
drocytes has been shown to play roles in cell survival
[14], proliferation [15] and process dynamics [16]. In
culture, activation of S1P receptor with fingolimod pro-
tected oligodendrocytes against apoptosis mediated by
growth factor deprivation in a mechanism linked to
extracellular signal-regulated kinase (ERK) 1/2 and akt
phosphorylation [14]. ERK phosphorylation has been
shown to be pro-survival in a number of relevant para-
digms, including in apoptosis mediated by glial-derived
reactive oxygen species. The relatively high concentra-
tion of fingolimod used in this study also elicited arrest
of oligodendrocyte differentiation, which was reversed
by neurotrophin 3 [17]; fingolimod in lower doses does
not arrest differentiation [15]. Fingolimod can also play
a role in platelet derived growth factor-induced oligo-
dendrocyte precursor cell (OPC) mitogenesis, in an
effect elicited by S1P1.
Oligodendrocyte process modulation by fingolimod
has been demonstrated in OPCs [16] and mature
human oligodendrocytes [18] in a time-dependent pro-
cess. Short-term fingolimod treatment of OPCs in
culture caused process retraction, while longer term
treatment led to process extension and enhanced survi-
val [16]. These studies demonstrated that S1P1 and
S1P5 mRNA transcripts are modulated by fingolimod in
a cyclical and reciprocal manner, leading to the time-
dependent effect. Finally, fingolimod has been shown to
increase remyelination when assessed morphologically in
brain slice cultures [19].
A microglial response to fingolimod has been postu-
lated, but this is as yet unclear. In a model of traumatic
brain injury [20] and of ischemia [21], fingolimod
reduced microglial activation as assessed by immunohis-
tochemistry. In the traumatic brain injury model, this
was associated with a reduction in apoptosis linked to
reduced microglia-derived interleukin 16 [22]. However,
others have found that non-cytotoxic microglial num-
bers are increased by fingolimod, but that their activa-
tion status remained unchanged [19].
Fingolimod has been shown to be cytotoxic to neu-
rons, at high concentrations in vitro [23]. At lower con-
centrations this toxicity was absent, and no evidence has
been produced that neuronal degeneration occurs in
other paradigms using the compound. In astrocytes,
ERK phosphorylation following fingolimod treatment
was shown [24]. Previously, ERK phosphorylation in
astrocytes has been shown to cause proliferation, though
this was not demonstrated in the study cited. Astrocyte
migration can also be elicited through S1P receptor sig-
naling [25].
The compound has also been shown to reduce clinical
signs in EAE, with the effects linked to reduced systemic
and CNS inflammation. Two separate studies in the DA
rat examined this from different viewpoints: gene
expression [26] and cellular inflammatory markers [27].
Genes encoding inflammatory mediators and vascular
adhesion molecules were down-regulated by treatment
with fingolimod. In addition, expression of matrix
metalloproteinase 9 and tissue inhibitor of metallopro-
teinase 1 were reduced, indicating a role for fingolimod
in maintenance of blood-brain barrier integrity. The sec-
ond study confirmed an attenuation of inflammatory
mediators including interferon gamma and nitric oxide
(NO), due to a reduction in CNS penetrant lympho-
cytes. Similar effects have been demonstrated in other
EAE models, in Lewis rat [28], SJL mice [29] and
C57BL/6 mice [30].
The reaggregate spheroid cell culture model employed
in this study myelinates over 25 days in vitro, and can
be demyelinated using lysophosphatidyl choline, follow-
ing which spontaneous remyelination occurs [31,32].
Pro-remyelinative effects can be elucidated by observing
augmentation of this remyelination. The model is devoid
of classical blood-borne immune cells, but contains
CNS-resident microglia (5-10% of total cell population
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[33]); therefore, effects on the CNS can be elucidated in
the absence of the immune system.
In this study we provide evidence for direct effects of
fingolimod on remyelination via dampening of the
microglial response, associated with a reduction in apop-
tosis and modulation of cytokine levels in the reaggre-
gate spheroid cell culture model.
Materials and methods
Animals
All animal experiments were performed in accordance
with the UK Animals (Scientific Procedures) Act 1984.
Time mated pregnant Sprague Dawley rats were
obtained from Charles River, Margate, UK.
Media and compounds
Mechanical dissociation and subsequent washes % cen-
trifugation were carried out in D1 solution [34], contain-
ing 138 mM NaCl, 5.4 mM KCl, 0.17 mM Na2HPO4,
0.22 mM KH2PO4, 5.55 mM D-glucose, 58.43 mM
sucrose, 5 mg%L phenol red (Invitrogen, Paisley, UK).
Aggregates were cultured in high glucose DMEM sup-
plemented with 10% fetal bovine serum (Invitrogen) and
100 U/ml penicillin-streptomycin (Invitrogen) as
described previously [31]. After 5 days in culture, med-
ium was further supplemented with 0.5 mM n-acetyl
cysteine (Sigma Aldrich, Poole, UK). Fingolimod,
AUY954 and BAF312 were supplied by Novartis Phar-
maceuticals, Basel, CH.
The rat CNS aggregate cell culture system
Fetuses were removed at embryonic age 16 days follow-
ing sacrifice of the adult by decapitation, and placed in
sterile, ice-cold D1 solution. The telencephalon was dis-
sected from each and pooled in ice-cold sterile D1 solu-
tion. After washing twice in D1 solution, brain tissue
was progressively dissociated by sieving through a 200-
μm followed by a 115- μm pore nylon mesh (Plastok,
Liverpool, UK). The filtrates were centrifuged at 300 g
for 15 min at 4°C, tested for viability using 0.1% trypan
blue exclusion, and re-centrifuged. The remaining tele-
ncephalon cell population was seeded at 4 × 107 cells
per flask and incubated at 37°C in a humidified 9%
CO2/91% O2 atmosphere (Heraeus incubator, Philip
Harris Scientific, Ashby-de-la-Zouch, UK) under con-
stant rotation at 83 rpm (Kuhner Shaker, Philip Harris
Scientific). The day of seeding was termed day in vitro
zero (DIV 0). Cells were transferred to larger flasks on
DIV 2, and the DMEM volume doubled to 8 ml. On
DIV 5, 8, 11, 14 and subsequently every other day, cul-
tures were fed by replacing 5 ml of pre-warmed DMEM
in each flask. Myelin basic protein is seen following DIV
14, and increases throughout the culture period, as does
neuronal marker neurofilament. This is in line with
development in the fetal brain at this time-point post-
partum [35,36], and reflects the developmental nature of
this model.
Demyelination and treatment protocol
0.14 mM lysophosphotidyl choline (Sigma) was added to
pre-warmed culture medium. Cultures were maintained
as described, substituting medium for lysophosphotidyl
choline-containing medium, on DIV 25 and 27. Lyso-
phosphotidyl choline was removed by medium replace-
ment three times on DIV 29. Control flasks were also
subjected to triple medium replacement. Treatment
with fingolimod, AUY954 or BAF312 commenced on
DIV23 and continued until DIV40. 3 μM fingolimod,
AUY954 or BAF312 was added to the culture medium
on each media replacement. Fingolimod was also tested
at a concentration of 1 and 10 nM, as effects had been
seen previously at low doses [19]. However, these con-
centrations elicited no changes in myelin basic protein
or microglial activation (data not shown). The concen-
tration used was therefore based on that of fingolimod
observed in the brain of lewis rats with EAE which were
given the compound [10]. Measured concentrations
were around 500 ng/g of tissue, which is equivalent to
around 1.5 μM. This was doubled to account for non-
specific binding to protein in the serum-containing
medium.
Sampling of aggregates
For confocal microscopy, aggregates were fixed in 4%
paraformaldehyde in phosphate buffer, pH 7, for 2
hours prior to washing and storage at 4°C in PBS con-
taining 0.01% sodium azide. For analysis by ELISA or
western blot, aggregate samples were homogenized by
sonication for 30 s in Tissue Protein Extraction Reagent
(T-PER; Pierce) with protease inhibitors (20 μg/ml leu-
peptin, 20 μg/ml pepstatin A, 200 μg/mlbenzoylarginine
methyl ester, 200 μg/mltosylarginine methyl ester, 200
μg/ml trypsin inhibitor, 200 μg/mltosylphenylalanyl
chloromethane, 200 μg/ml aprotinin and 4 mM ethyl
glycol tetra-acetic acid). Total protein was assayed using
the BCA kit (Thermo Fisher, Cramlington, UK) with
bovine serum albumin as a standard. For analysis of
cytokines on the Mesoscale Discovery platform, culture
medium was sampled, frozen on dry ice and stored at
-20°C.
Confocal microscopy
Free-floating whole aggregates were stained by incuba-
tion overnight at 4°C under constant inverting rotation
with a relevant primary antibody (goat anti-NFH,
AbCam, Cambridge, UK) in phosphate buffered saline
plus 0.1% Tween-20 (PBS-T). After washing three times
for 1 hour under constant inverting rotation with PBS-
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T, aggregates were labeled with a second primary anti-
body overnight (rabbit anti-MBP, AbCam) using the
same method. Following a further wash, relevant fluoro-
chrome-conjugated secondary antibodies were applied
and aggregates incubated overnight as previously. After
immunolabelling, aggregates were placed on a glass
microscope slide (VWR International Ltd, Lutterworth,
UK) followed by a drop of PBS/glycerol (1:8). A glass
cover slip was then placed on top of the aggregates, and
sealed. Aggregates were analysed on a Zeiss LSM laser
scanning confocal microscope.
Measurement of myelin basic protein, neurofilament H,
ferritin and nitric oxide by ELISA
Nitric oxide was measured using a Total Nitric Oxide
and Nitrate/Nitrite Parameter Assay Kit according to
manufacturer’s instructions (R&D Systems, Abingdon,
UK) following filtration of samples to remove high
molecular weight protein components using a centrifu-
gal device (Millipore, Watford, UK). Antibodies used for
the myelin basic protein (MBP, [37]), neurofilament (Nf,
[37]) and ferritin (Fe; [38]) ELISAs have been described
previously. Coat antibody was diluted in coating buffer
(100 mm Na2HPO4 adjusted to pH 9.0 with 100 mm
NaH2PO4), and 100 μL was added to each well of a 96-
well NuncMaxisorp plate (VWR International). The
plate was then incubated overnight at 4°C. After bring-
ing the plate to room temperature, it was washed once
using PBS-T (Sigma). Non-specific binding was blocked
by incubation with 1% bovine serum albumin (Sigma) in
PBS-T for 1 hour at room temperature. Following
blocking, the plate was washed once using PBS-T and
then incubated with diluted samples and standards for 2
h at room temperature under gentle agitation. After
washing four times as above, the detect antibody was
applied at 1:1000 and the plate incubated as previously
for 1 h. For MBP and Nf, horseradish peroxidase-conju-
gated reporter antibody was applied at 1:1000 and the
plate was incubated for 1 h at room temperature. The
secondary antibody in the ferritin ELISA is directly con-
jugated to HRP, so this was not necessary for this ana-
lyte. TMB Substrate (R and D Systems UK Ltd,
Abingdon, UK) was applied following four final washes,
and the colour developed for 15 min before being
stopped with 1 m phosphoric acid. The plate was read
on a photometer (AnthosLabtec Instruments, Salzburg,
Austria) at 450 nm wavelength, using 620 nm wave-
length as a reference measurement.
Mesoscale Discovery Platform multiplex cytokine
measurements
To assess the concentrations of cytokines in the culture
medium samples were assessed using the Mesoscale Dis-
covery Platform multiplex system, according to
manufacturer’s instructions. Briefly, non-specific binding
on the plate was blocked with bovine serum albumin
and sample added to each well. Following incubation,
washing, and secondary antibody cocktail incubation,
the plate was read on a MSD SECTOR Imager 2400.
Measurement of Caspase 3 Western blotting
Proteins were separated using sodium docylsulphate
polyacrylamide gel electrophoresis using a mini-protean
system (Bio-Rad, Hemel Hempstead, UK). Protein was
run on a 12% tris-glycine gel (BioRad), transferred to
nitrocellulose membrane, blocked with 5% fat-free milk
and probed with the antibodies active and pro caspase 3
(AbCam). Following incubation with an appropriate
HRP-conjugated secondary antibody (Dako, Ely, UK),
visualisation was carried out using the ECL detection
system (GE Healthcare, Little Chalfont, UK), and the
membrane was exposed to radiological film. Band den-
sity was measured using computer, and normalised to
GAPDH as a loading control.
Electron Microscopy for identification of myelin structures
Spheroids were washed with sterile PBS (Gibco) and
fixed for 3 hours in EM fixative (2% Paraformaldehyde
2.5% gluteraldehyde in 0.1 M phosphate buffer) before
being post fixed for 2 hours in osmium tetroxide. Fol-
lowing embedding in araldite resin (Agar), 1 micron sec-
tions were cut and stained, and viewed on a Hitachi
H7600 transmission electron microscope.
Results
Fingolimod increases myelin basic protein following a
demyelinative insult
Myelinated neurospheres were demyelinated by transient
treatment with lysophosphotidyl choline from DIV 25 to
DIV 29. Neurofilament levels as measured by ELISA did
not significantly change over the demyelination period
or following recovery, indicating that axonal damage
was not a significant component of pathology in this
model (Figure 1). This also indicates that the observed
MBP level increase was not due to myelination of fingo-
limod-induced de novo neuronal sprouting. The trend
towards increasing NF levels can be attributed to the
developmental nature of the model. Myelin basic protein
expression was measured by ELISA, and fluorescent
staining for MBP in spheroids was analysed using laser
scanning confocal microscopy, as a surrogate marker for
myelination status. MBP levels were significantly
reduced following lysophosphotidyl choline-induced
demyelinative insult, and this was not altered by the
presence of fingolimod (Figure 1). At DIV 40, MBP
levels in demyelinated cultures had returned to that of
control, indicating that the spontaneous remyelination
associated with this model had occurred. The MBP level
Jackson et al. Journal of Neuroinflammation 2011, 8:76
http://www.jneuroinflammation.com/content/8/1/76
Page 4 of 12
in fingolimod treated cultures rebounded beyond the
control level, and was significantly higher at this last time
point, indicating an enhancement of remyelination.
These results were morphologically corroborated by con-
focal microscopy for MBP and neurofilament (Figure 2).
To confirm the presence of morphologically complete
multi-lamellar myelin, electron microscopy was per-
formed on spheroids from each time point. Spheroids
were examined for presence of morphological indicators
of myelination, demyelination and remyelination. Prior
to demyelination, compact myelin could be identified in
neurospheres by identification of concentric tightly
packed rings of electron dense material, complete with
characteristic major dense lines. These were not present
following lysophosphatidyl choline treatment, indicating
demyelination had occurred similarly in fingolimod trea-
ted and control cultures. Following the recovery period,
multi-lamellar myelin was once again present in the
spheres, indicating remyelination had occurred (Figure
2). The g-ratio of fibre diameter to fibre plus myelin dia-
meter was measured to assess the extent of remyelina-
tion, and to identify thin myelin sheaths characteristic of
remyelination (Figure 1). G-ratio measurements from
pre-demyelinated neurospheres indicated that the g-
ratio values agreed with previously published measure-
ments of myelin thickness in vivo. However, the range
of g-ratio values was extended compared to published in
vivo values, indicating that in this culture system, myelin
thickness and axonal diameter are less closely co-regu-
lated than in the in vivo situation. Following remyelina-
tion, g-ratio values were not increased, as could be
expected from in vivo studies, indicating a lack of char-
acteristic remyelinated fibres. There was no significant
difference in fingolimod treated cultures compared with
control.
Fingolimod negatively regulates markers of inflammation
in the absence of lymphocytes and immune organs
In order to evaluate the impact of fingolimod on micro-
glia, an ELISA for ferritin was performed, as increased
ferritin levels are indicative of microglial activation (Fig-
ure 3A; [38]). Ferritin levels increased following demyeli-
nation, and had returned to control levels following
remyelination. Fingolimod reduced, but did not abolish,
this increase in ferritin immunoreactivity, indicating that
the compound partially inhibited the development of
microglial activation.
In order to assess the presence of microglia/astrocyte-
derived pathological indicators, NO metabolites were
measured (Figure 3B). The cultures were found to have
a high ‘background’ level of NO metabolites, which was
significantly increased following demyelination. This
increase was abolished in fingolimod-treated cultures.
In order to examine the impact of fingolimod on the
immune microenvironment of the CNS, cytokines
involved in the inflammatory process were measured
(Figure 4). Demyelination resulted in an increase in the
levels of tumor necrosis factor alpha (TNF-a) and inter-
leukin (IL)-1b which was abolished by fingolimod
Figure 1 Spheroid myelinating cultures were prepared from
fetal rat telencephalon and demyelinated with
lysophosphotidyl choline on DIV 25-29 in the presence or
absence of fingolimod. Myelin basic protein (A) and neurofilament
(B) levels were measured using protein specific ELISA following
demyelination. C) Spheroids were fixed and processed for electron
microscopy. The mean ratio (+/- SEM) of fibre diameter to myelin
thickness was determined (G-ratio) in a minimum of 10 fibres per
sample from 3 samples per group. Results were analysed by ANOVA
with Holm-Sidak post test. * = p < 0.05; ** = p < 0.01.
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treatment. Following remyelination, IL-1b in lysopho-
sphotidyl choline-treated spheroids were significantly
higher than controls, indicating a transient effect of fin-
golimod. Levels of TNF-a were significantly reduced in
all cultures following remyelination.
Fingolimod reduces apoptosis following a demyelinative
insult
Demyelinative treatment of spheroids has been shown to
induce apoptosis [39]. In order to assess the impact of fin-
golimod on apoptosis in this system, western blotting was
performed for intact (non-activated) and cleaved (acti-
vated) caspase 3 following demyelinative insult (Figure
5A). Fingolimod treated cultures expressed less intact cas-
pase 3 than control cultures, none of which was cleaved to
the active form. This indicated a significant reduction in
caspase 3 production and activation, as was confirmed by
using the CaspaTag staining system for caspase 3 and 7
(Figure 5B). Staining with CaspaTag increased following
demyelination, and this increase was significantly
attenuated by fingolimod. CaspaTag staining fell to pre-
vious low levels following the recovery period, suggesting
that demyelination-induced apoptosis is a transient event.
S1P5, but not S1P1, agonism elicits enhanced
remyelination in vitro
Aggregates were seeded, allowed to mature and demyeli-
nated as previously, and treated over the same period
with AUY954, active at S1P1, or BAF312, active at S1P1
and S1P5. Aggregates were analysed for MBP and NF
content by ELISA. Cultures treated with BAF312 exhib-
ited a significant rebound in MBP levels following
demyelination compared with control, whereas cultures
treated with AUY954 did not (Figure 6). This indicates
that agonism at S1P1 is not sufficient to elicit changes
in remyelination, but that this may be mediated through
signaling at S1P5. Neurofilament levels were unchanged
between groups, and were not affected by the demyeli-
native insult, indicating that the effect on MBP was not
due to de novo axonal sprouting.
Figure 2 Spheroid myelinating cultures were prepared from fetal rat telencephalon and demyelinated with lysophosphotidyl choline
on DIV 25-29 in the presence or absence of fingolimod. Confocal and electron microscopy was carried out to determine morphology of
myelinated fibres. Spheroids were fixed and stained whole with specific antibodies against myelin basic protein (green) and neurofilament (red)
after demyelination (A) and following remyelination (B). Spheroids prepared for electron microscopy were imaged to assess morphology prior to
demyelination (C) and following remyelination (D).
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Discussion
This paper describes direct effects of fingolimod on cells
of the rat CNS. Here, we demonstrate that fingolimod
can actively promote remyelination following an insult
elicited by lysophosphotidyl choline, indicating direct
interaction of fingolimod with oligodendrocytes, micro-
glia and/or astrocytes.
Fingolimod increased markers of myelination as
assessed biochemically and morphologically in a culture
model lacking monocytes and other components of the
immune system, but including microglia. Fingolimod
has been shown to reduce pathology associated with
demyelination in vivo models, although this can largely
be attributed to sequestration of reactive T lymphocytes
in lymphoid organs. Fingolimod has also been shown to
alter myelin gene expression, and preferentially localises
to myelin tracts in vivo [10]. In culture, fingolimod
exerts dose-dependent effects on OPCs, and can prevent
OPC apoptosis and differentiation [16]. OPCs are
thought to be intimately involved in the remyelination
process in humans, and OPC dysfunction may be one
factor preventing remyelination in MS [40].
Figure 3 Spheroid myelinating cultures were prepared from
fetal rat telencephalon and demyelinated with
lysophosphotidyl choline on DIV 25-29 in the presence or
absence of fingolimod. Samples of spheroids were homogenised
in protein extraction buffer, centrifuged and the supernatant
removed. Samples were analysed by ELISA for (A) ferritin and (B)
nitric oxide over the course of demyelination and remyelination.
Results were analysed by ANOVA with Holm-Sidak post test, and are
expressed as mean +/- SEM, n = 10. * = p < 0.05; ** = p < 0.01.
Figure 4 Spheroid myelinating cultures were prepared from
fetal rat telencephalon and demyelinated with
lysophosphotidyl choline on DIV 25-29 in the presence or
absence of fingolimod. Multiplex ELISA was used to analyse
cytokine production in tissue culture supernatant. Culture medium
was snap frozen and subsequently analysed using the Mesoscale
Discovery Platform. Mean levels of tumor necrosis factor alpha and
interleukin 1b were determined and expressed per milligram total
protein +/- SEM (n = 10 per goup). ** = p < 0.01.
Jackson et al. Journal of Neuroinflammation 2011, 8:76
http://www.jneuroinflammation.com/content/8/1/76
Page 7 of 12
Oligodendrocyte progenitors and precursors are present
in the spheroid cultures, and persist after demyelination
[41]. The full range of oligodendrocyte progenitor and
precursor markers have been identified by fluorescent
immunostaining, and include platelet derived growth
factor alpha receptor, NG2 chondroitin sulphate, O4
and galactocerebroside. Early markers decline by the
point at which demyelination is induced, but are still
present; pre-myelinating O4 and galactocerebroside
positive oligodendrocytes are present in higher numbers
around the point at which demyelination is induced,
providing a source of potentially remyelinating
oligodendrocytes.
Interestingly, agonism of S1P receptor 5 increased
myelin basic protein levels above those of control, indi-
cating a role for this receptor in remyelination. This
effect was not observed using an agonist to S1P1, indi-
cating a heterogenous role for these receptors in remye-
lination. This agrees with previously published in vitro
results, showing that S1P5 activation can induce changes
in oligodendrocyte morphology and myelination [15,19].
Differences in G-protein coupled receptor signaling may
Figure 5 Spheroid myelinating cultures were prepared from fetal rat telencephalon and demyelinated with lysophosphotidyl choline
on DIV 25-29 in the presence or absence of fingolimod. Pro-caspase 3 and caspase 3 levels were assessed in homogenized spheroids with
western blot (A, B) following homogenization and separation on polyacrylamide gel (n = 4; ** = p < 0.01; *** = p < 0.001). Caspase 3 and 7
activity were assessed in intact spheroids using the CaspaTag staining system (C, D) followed by fluorophore conjugation and confocal
microscopy (n = 8; ** = p < 0.01). Results were analysed by ANOVA with Holm-Sidak post test.
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underlie the hetrogenous effects observed-S1P1 signals
using G ai/o only, employing cAMP as a secondary
messenger, whereas S1P5 can also signal via G a12/13
which signals via the Rho GTPase [42]. Rho signaling
has been shown to regulate oligdendrocyte precursor
cell cycle events via a network of positive and negative
regulators [16,43].
Lysophosphotidyl choline has been postulated to cause
demyelination via several routes. It has been shown to
act as a lipodestructive detergent with the ability to pre-
ferentially destroy lipid-rich membranes of myelin
sheaths. These structures are highly susceptible to ionic
detergent activity. Importantly for this study, lysopho-
sphotidyl choline has also been shown to elicit activa-
tion of microglia [44] as assessed morphologically [45]
and by cytokine production [46], providing another
route for demyelination. In addition, specific G-protein
receptor and microtubule associated protein kinase-
mediated interactions between lysophosphotidyl choline
and the oligodendrocyte have been uncovered, opening
the potential for ligand mediated cell death. Apoptosis is
reduced in this culture system by fingolimod but it is
unlikely that fingolimod reduced apoptosis via ligand-
mediated effects [47]. It is more likely that reduction of
microglia/astrocyte-derived factors and modulation of
the pathological milieu was responsible for a reduction
in apoptosis. The identity of these apoptotic cells in the
spheroids was not probed in this study; this could be
examined in primary monolayer cultures where enu-
meration of apoptotic vs. normal cells could be more
effectively performed. Given the paradigm used, the
authors predict that oligodendrocytes will be the cells
susceptible to apoptosis.
Fingolimod altered the in vitro microenvironment via
direct effects on microglia and possibly astrocytes.
Demyelination resulted in the expression of the cyto-
kines TNF-a and IL1b which were down-regulated by
treatment with fingolimod. These cytokines are pro-
duced by activated microglia and astrocytes, and are
pathological effectors in EAE and MS. Microglial activa-
tion in MS is seen acutely during demyelination, and
motile activated macrophages can contribute to demyeli-
nation or repair. Microglia are also chronically activated
in normal appearing white matter during MS, and may
contribute to axonal damage. Molecules which modulate
microglial activation have been shown to be effective in
experimental models of MS, including EAE. In this
model, demyelination also caused an up regulation in
NO species, albeit against a high background of NO.
This significant rise was attenuated by fingolimod, likely
by effects on microglia and astrocytes. Given that dis-
ease modification with fingolimod is possible in
ischemic and brain injury models via dampening micro-
glial response [22,48], it is feasible that fingolimod
would also modulate secondary disease in MS models.
However, recent data from this group [49] contradicts
this hypothesis, with fingolimod having no effect on
progressive secondary experimental autoimmune ence-
phalomyelitis. In the acute non-gliotic disease state, fin-
golimod provides protection in this model, providing
evidence to suggest FTY720 will not elicit repair beyond
a certain disease stage. In addition, recent data has been
published showing that FTY720 does not elicit remyeli-
nation in the non-inflammatory cuprizone model,
further strengthening the notion that the neuroprotec-
tive effects of FTY720 are mediated by dampening the
inflammatory process [50].
The findings presented are in agreement with previous
published studies. S1P1 receptor activation modulates
phosphorylation of ERK, which has been shown to pro-
tect oligodendrocytes from microglia-derived, reactive
Figure 6 Spheroid myelinating cultures were prepared from
fetal rat telencephalon and demyelinated with
lysophosphotidyl choline on DIV 25-29 in the presence or
absence of AUY954, an S1P1 agonist, or BAF312, an S1P1 and
S1P5 agonist. Myelin basic protein (A) and neurofilament (B) levels
were measured using protein specific ELISA following
demyelination. Results were analysed by ANOVA with Holm-Sidak
post test. * = p < 0.05; ** = p < 0.01.
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species-mediated apoptosis [14]. In this study, fingoli-
mod was found to down-regulate NO species produc-
tion following demyelination. In addition, fingolimod
has been shown to protect OPCs from microglial condi-
tioned medium induced cell death, mediated by the pro-
inflammatory cytokines interferon gamma and TNF-a
[51]. Again, fingolimod was shown to modulate IL1b
and TNF-a production following insult in this model,
indicating effects on microglia. In models of traumatic
brain injury, fingolimod has been shown to attenuate
major histocompatibility complex II and Endothelial
monocyte-activating polypeptide II expression indicating
an anti-inflammatory role [22]. In addition, activation of
S1P receptors in a rodent model of cerebral ischemia
has been shown to protect against neuronal cell death,
reducing infarct volume by down-regulation of micro-
glial activation [48]. Microglia and, to a lesser extent,
astrocytes have also been shown to produce IL16 in
response to immunological challenge, and fingolimod
has been shown to be able to reduce production of this
cytokine [20].
Myelin basic protein was used as a surrogate marker for
myelination in this study, as it is expressed as a late mar-
ker of myelination, and is involved in the final stages of
myelination - compaction. The protein has been used as a
marker of mature myelin in ex vivo and in vitro material
[52], and correlates with myelination in this system [39].
As is the case in vivo, it has been shown that remyelination
in this system is dependent on the presence of microglia/
macrophages which elicit myelin clearance in short time-
frames [53]. In the spheroid cultures, the g-ratio values
were comparable with those of other in vivo and in vitro
models [54-57], and were reduced as expect following
demyelination. However, the characteristic higher g-ratio
values following remyelination seen in vivo were not
observed in this study, with g-ratios returning to those of
pre-demyelinated axons. This indicates that compaction
during the remyelination phase differs between the in vivo
and in vitro situation. This could be attributed to a smaller
number of lamellar wraps, often coincident with shorted
internodal distances. It is also known that axons increase
diameter in response to myelination by hyperphosphoryla-
tion of neurofilaments. These processes may be altered in
a system that has developed and is maintained with no
spatial restriction or competition, such as the spheroid
model employed here.
It is interesting that, while it was able to modulate the
remyelination phase, fingolimod did not have any effect
on the initial demyelinative event. This is perhaps not
surprising when considering the method of insult. The
primary effect of lysophosphotidyl choline on myelin is
a toxic event occurring through lipid peroxidation, and
this is likely to occur rapidly in vitro [58]. The effect on
microglia is likely to be slower [59], and therefore
microglial activation would peak at a later time-point,
following the majority of myelin damage. However,
microglial activation persists following this acute insult.
We postulate that it is this prolonged microglial activa-
tion against which fingolimod is acting to produce
enhanced remyelination.
Spheroids are allowed to recover for 11 days in order
to monitor remyelination. This relatively short time-per-
iod is in excess of other similar published methods:
remyelination is seen after 3 [40] or 11 days [60] in slice
cultures following transient insult, indicating that these
timeframes are applicable. Indeed in animal models
using lysophosphotidyl choline, remyelination can be
observed in a similar timeframe [61,62]
The aggregating spheroid telencephalon system has
proved a useful model of inflammatory demyelination in
this study. As well as providing robust myelination and
remyelination, the system allows probing of the effects
directly on cells of the CNS in the absence of peripheral
immune components. In addition, it allows for multi-
time point sampling of the same population of cells, and
provides the ability for imaging and biochemical/mole-
cular analysis on this same population. However, this
study has also detailed some less favorable aspects of
the model, namely the lack of correlation of g-ratio
values with in vivo remyelination. The data presented
give some insight into the mechanism of action of
demyelination in this paradigm. In the absence of
monocytes, microglia and astrocytes are able to produce
pro-inflammatory cytokines and reactive oxygen species
responsible for demyelination.
The actions of fingolimod on microglial cells indicated
here may be extrapolated into the clinical setting, and
could result in increased remyelination. In addition to
reducing autoimmunity and indirectly allowing natural
reparative mechanisms to take place via effects on T-cells,
these results indicate that fingolimod may also directly
facilitate the remyelinative process through effects on
microglia, and thus influence the progression of MS.
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